gilteritinib + azacitidine
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Acute Myeloid Leukemia (AML)
Conditions
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
Trial Timeline
Aug 1, 2016 → Dec 18, 2024
NCT ID
NCT02752035About gilteritinib + azacitidine
gilteritinib + azacitidine is a phase 3 stage product being developed by Astellas Pharma for Acute Myeloid Leukemia (AML). The current trial status is completed. This product is registered under clinical trial identifier NCT02752035. Target conditions include Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation.
What happened to similar drugs?
20 of 20 similar drugs in Acute Myeloid Leukemia (AML) were approved
Approved (20) Terminated (4) Active (0)
✅Modification of Prasugrel based on a biological assay + prasugrel / clopidogrelDaiichi SankyoApproved
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02752035 | Phase 3 | Completed |
Competing Products
20 competing products in Acute Myeloid Leukemia (AML)